The Cronos App beta version has begun opening to a select group of registered users. Screenshots of the beta interface shown by Cronos App CEO Ryan Wyatt indicate that the platform will offer stock trading functionality, with the Intel (Intel, stock code INTC) sample page displaying leverage up to 10x.

This news triggered a rebound in CRO prices. Prices recovered from the lower edge of the long-term demand zone, but the upward momentum quickly slowed, failing to break through the resistance area near the 20-week exponential moving average.

The beta version will be available to early adopters first.

Ryan Wyatt stated that the beta version is currently being rolled out gradually to registered users, and the team will collect early feedback before pushing for a wider rollout. The market therefore views this update as a new attempt by Cronos to expand its product scenarios.

However, judging from price performance, buying interest remains limited. Product news has brought short-term attention, but has not yet driven CROs to establish a clearer upward trend.

Prices remain suppressed by key resistance levels.

The article indicates that CRO is currently consolidating near the lower end of its trading range. While the beta version news improved short-term sentiment, the price failed to break above the 20-week EMA, suggesting that current resistance remains significant.

If demand continues to strengthen and drives prices back above this moving average area, CRO may continue to recover from the support level of around $0.060 and move towards the $0.100 level.

The $0.060 support level remains a key focus.

The downside risks have not yet been eliminated. The article mentions that since January 2026, the rising wedge pattern on the weekly chart for CRO has broken downwards, and the overall trend remains weak.

If the $0.060 support level is breached, prices could fall further and risk hitting new all-time lows. In the short term, whether the optimism generated by the beta launch can translate into sustained buying interest remains a key focus for the market.